S. Schapmans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Schapmans has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
C D'Hont
1 shared publicationJ Cortvriend
1 shared publicationJ. Cortvriend
1 shared publicationL J Denis
1 shared publicationL. Van Leuven
1 shared publicationP Van Erps
Department of Urology, AZ Middelheim, Antwerp
1 shared publication
Latest Publications
- 1 January 2000
- Published by Elsevier in European Urology
- Vol. 38 (5) , 649-653
Phyllodes Tumor of the Prostate
Prostatic cystic epithelial–stromal tumors, commonly described as phyllodes tumors of the prostate, are extremely rare lesions. They exhibit a spectrum of histological features similar to their better known counterpart in the breast. Although a benign clinical course has been emphasized in some reports, cumulative evidence in the literature indicates that these lesions should be considered neoplasms rather than atypical hyperplasia due to the frequent early recurrences with possible dedifferentiation, infiltrative growth and potential for extraprostatic spread in some cases. An individualized approach to complete excision of the tumor is needed. A case record of a patient recently treated at our medical center with a low–grade phyllodes tumor is presented and a review of the literature was done.
- 1 January 2000
- Published by Elsevier in European Urology
- Vol. 38 (5) , 649-653
Phyllodes Tumor of the Prostate
Prostatic cystic epithelial–stromal tumors, commonly described as phyllodes tumors of the prostate, are extremely rare lesions. They exhibit a spectrum of histological features similar to their better known counterpart in the breast. Although a benign clinical course has been emphasized in some reports, cumulative evidence in the literature indicates that these lesions should be considered neoplasms rather than atypical hyperplasia due to the frequent early recurrences with possible dedifferentiation, infiltrative growth and potential for extraprostatic spread in some cases. An individualized approach to complete excision of the tumor is needed. A case record of a patient recently treated at our medical center with a low–grade phyllodes tumor is presented and a review of the literature was done.
- 1 September 1995
- Vol. 63 (3) , 39-43
Urodynamic effects of Prolase 2 laser prostatectomy in benign prostatic hyperplasia.
This prospective study was undertaken to evaluate the safety and efficacy of visual laser ablation of the prostate with the Prolase 2 sidefiring neodymium: YAG laser fiber in patients with symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). The Prolase 2 fiber is a non-contact sidefiring fiber, producing coagulation of the prostatic tissue. Our study describes the results obtained in 30 patients who underwent VLAP with a mean follow-up of 6 months. The evaluation of symptoms according to the WHO International Prostate Symptom Score and Quality of Life Score (IPSS and QL) demonstrated a significant subjective response rate (p < 0.001). Objective assessment of treatment with peak and average urinary flow rates, post-void residual urine volumes and pressure-flow urodynamic studies showed a significant improvement after treatment (p < 0.001). Ultrasonic assessment of prostatic volumes at 6 months showed a mean decrease in total volume of 37% after laser prostatectomy. The early and late complications of the treatment are presented but overall toxicity is low. Laser prostatectomy performed with the Prolase 2 fiber seems to be safe and efficacious for BPH patients but long term efficacy and retreatment rates have to be awaited.
- 1 September 1995
- Vol. 63 (3) , 39-43
Urodynamic effects of Prolase 2 laser prostatectomy in benign prostatic hyperplasia.
This prospective study was undertaken to evaluate the safety and efficacy of visual laser ablation of the prostate with the Prolase 2 sidefiring neodymium: YAG laser fiber in patients with symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). The Prolase 2 fiber is a non-contact sidefiring fiber, producing coagulation of the prostatic tissue. Our study describes the results obtained in 30 patients who underwent VLAP with a mean follow-up of 6 months. The evaluation of symptoms according to the WHO International Prostate Symptom Score and Quality of Life Score (IPSS and QL) demonstrated a significant subjective response rate (p < 0.001). Objective assessment of treatment with peak and average urinary flow rates, post-void residual urine volumes and pressure-flow urodynamic studies showed a significant improvement after treatment (p < 0.001). Ultrasonic assessment of prostatic volumes at 6 months showed a mean decrease in total volume of 37% after laser prostatectomy. The early and late complications of the treatment are presented but overall toxicity is low. Laser prostatectomy performed with the Prolase 2 fiber seems to be safe and efficacious for BPH patients but long term efficacy and retreatment rates have to be awaited.